Loading clinical trials...

Remimazolam and Emergence Delirium in Pediatrics | Clinical Trials | Clareo Health

RECRUITINGPHASE4

Remimazolam and Emergence Delirium in Pediatrics

The Effect of Remimazolam on Emergence Delirium in Pediatrics Undergoing Neurosurgery With Sevoflurane Anesthesia

NCT07046364•Peking University First Hospital

Summary

Emergence delirium is a common complication in pediatrics undergoing neurosurgery. Previous study showed that a single bolus of remimazolam was associated with lower incidence of postoperative agitation. Present study was designed to investigate if remimazolam supplemented to sevoflurane anesthesia could decrease the risk of emergence delirium in pediatrics undergoing neurosurgery.

Eligibility

Age

1 - 6 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Aged 1 to 6 years old
•Planned to receive elective neurosurgery under general anesthesia
•Expected duration of surgery \> 1 hour

Exclusion Criteria

•Allergy to benzodiazepine
•Use of other sedatives within 12 hours before surgery such as benzodiazepines, propofol, chloral hydrate, etc.,
•ASA classification IV or above
•Unable to complete emergence delirium assessment, such as language, hearing or vision impairment.

Locations (2)

Peking University First Hospital

Beijing, Beijing Municipality, China

Peking University First Hospital

Beijing, Beijing Municipality, China

Key Dates

Start Date

January 1, 2025

Primary Completion Date

January 1, 2027

Completion Date

January 1, 2027

Last Updated

July 1, 2025

Enrollment

248

ESTIMATED participants

Conditions

PediatricNeurosurgerySevoflurane AnesthesiaRemimazolamEmergence Delirium

Interventions

Remimazolam

DRUG

Normal Saline

DRUG

Contacts

Dong-liang Mu

CONTACT

+86 010 83575138 mudongliang@bjmu.edu.cn

Transcutaneous pO₂ Monitoring in PICU

NCT07478380

Pediatric Critical Illness

View study

RECRUITINGPHASE1

Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies

NCT05011422

Pediatric Hematologic Malignancies

View study

RECRUITINGPHASE2/PHASE3

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

NCT05267821

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 1, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Remimazolam and Emergence Delirium in Pediatrics

Inclusion Criteria

Exclusion Criteria

Transcutaneous pO₂ Monitoring in PICU

Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

Premedication in Children: a Clinical Trial Comparing Oral Ketamine and Oral Clonidine With Respect to Sedation Level and Opioid Consumption in Pediatrics Undergoing Elective Lower Abdominal Day-case Surgery.

Heart Rate Variability and Processed EEG Features as Predictors of Postoperative Outcomes After Cranial Neurosurgery

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma